[{"from": "human", "value": "Provide a description of this molecule. [C][C@@][Branch2][Ring2][#Branch1][C][=Branch1][C][=O][N][C@H1][Branch2][Ring1][Branch1][C][=Branch1][C][=O][N][C][C][C][C@H1][Ring1][Branch1][C@@][Ring1][#Branch2][Branch1][Ring2][O][Ring1][=C][O][C][C][=C][C][=C][C][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][C@@H1][C][C@H1][C@@H1][Branch1][P][C][C][=C][N][C][=C][C][=C][C][Ring1][O][=C][Ring1][=Branch2][Ring1][=Branch1][N][Branch1][Ring2][C][Ring1][S][C].[C][S][=Branch1][C][=O][=Branch1][C][=O][O]"}, {"from": "gpt", "value": "The molecule is an ergot derivative with agonistic activity for alpha-adrenergic, serotonergic, and dopaminergic receptors. Dihydroergotamine mesylate most likely relieves migraine headaches by binding to and stimulating the 5-HT1D receptor subtype, thereby causing constriction of cerebral blood vessels. However, it has also been proposed that dihydroergotamine mesylate acts upon 5-HT1D receptors on sensory nerve endings of the trigeminal system, thereby decreasing the release of pro-inflammatory neuropeptide release."}]